Summary
In 11 patients with stable premature ventricular beats, the kinetics of single (150 and 300 mg) and multiple (150 mg t.i.d. and 300 mg t.i.d.) oral doses of propafenone were studied with reference to arrhythmia suppression. During the acute phase detectable plasma levels of the drug were achieved only with the higher dose. In 8 out of 10 patients the antiarrhythmic effect was obtained with the 300 mg dose, which was found to predict responsiveness at steady-state. During the chronic phase, antiarrhythmic efficacy was obtained with the lower dose regimen (150 mg t.i.d.) in half of those patients.
A wide range of effective plasma levels was observed. The previously suggested therapeutic range (0.5–2.0 µg/ml) was not adequate in predicting either antiarrhythmic activity or adverse effects. The results show the role of propafenone metabolites in determining total antiarrhythmic action.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vaughan Williams EM (1975) Classification of antiarrhythmic drugs. Pharmacol Ther (B) 1: 115–138
Scholz H (1983) The pharmacology of propafenone. In: Schlepper M, Olsson B (eds) Cardiac arrhythmias. Diagnosis, prognosis, therapy. Springer, Berlin Heidelberg New York: 103–111
Seipel L, Breithardt G (1980) Propafenone: A new antiarrhythmic drug. Eur Heart J 1: 309–313
Naccarella F, Bracchetti D, Palmieri M, Marchesini B, Ambrosioni E, Magnani B (1984) Propafenone for refractory ventricular arrhythmias. Correlation with drug plasma levels during long term treatment. Am J Cardiol 54: 1008–1014
Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA (1983) Clinical pharmacology of propafenone. Circulation 68: 589–596
Hollman M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforsch (Drug Res) 33: 763–770
Siddoway LA, McAllister CB, Wang T, Bergstrand RH, Roden DM, Wilkinson GR, Woosley RL (1983) Polymorphic oxidative metabolism of propafenone in man. Circulation (Abs) 68 [Suppl 3]: 253
Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 17: 353–360
Morganroth U, Michelson EL, Horowitz LN (1978) Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 58: 408–416
Brode E, Sachse R, Hoffmann HD (1982) Untersuchungen zur Analytik von Propafenone mittels interner Analogstandardisierung. Arzneimittelforsch (Drug Res) 32: 1–6
Marchesini B, Boschi S, Berti C (1983) Identification of a metabolite of propafenone in human urine by means of high-performance liquid chromatography and gas chromatographymass spectrometry J Chromatogr 278: 173–178
Hege HG, Hollman M, Kaumeier S, Lietz H (1984) The metabolic fate of 2H-labeled propafenone in man. Eur J Drug Metabol Pharmacol 9: 41–55
Salerno DM, Granrud G, Sharkey P, Asinger R, Hodges M (1983) A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. Am J Cardiol 53: 77–83
Connolly SJ, Lebsack CS, Winkle RA, Harrison DC, Kates RE (1984) Propafenone disposition kinetics in cardiac arrhythmia. Clin Pharmacol Ther 36: 163–168
Keller K, Meyer-Estorf G, Beck OA, Hochrein H (1978) Correlation between serum concentration and pharmacological effect on atrioventricular conduction of the antiarrhythmic drug Propafenone. Eur J Clin Pharmacol 13: 17–20
Von Philipsborn G, Gries J, Hofmann HP, Kreiskott H, Kretzschmar R, Muller CD, Raschack M, Teschendorf J (1984) Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforsch (Drug Res) 34 [II] 1489–1492
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frabetti, L., Marchesini, B., Capucci, A. et al. Antiarrhythmic efficacy of propafenone: Evaluation of effective plasma levels following single and multiple doses. Eur J Clin Pharmacol 30, 665–671 (1986). https://doi.org/10.1007/BF00608213
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00608213